David Hagin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
David Hagin has a total of 306 co-authors. Here are the top co-authors by number of shared publications:
- Natalia T. Freund
Department for Microbiology and Clinical Immunology, Faculty of Medicine, Tel Aviv University, Israel
6 shared publications - Troy Robert Torgerson
Allen Institute for Immunology
4 shared publications Michal Navon
Department of Clinical Microbiology and Immunology, Sackler Faculty of Medicine, Tel Aviv University, Israel
3 shared publications- Oren Kobiler
Department of Clinical Microbiology and Immunology, Gray Faculty of Medical and Health Sciences, Tel Aviv University, Tel Aviv, Israel
3 shared publications - Ron Ram
Gray Faculty of Medical and Health Sciences, Tel Aviv University, Israel
3 shared publications - Yifat Alcalay
Allergy and Clinical Immunology Unit, Department of Medicine, Tel-Aviv Sourasky Medical Center and Sackler Faculty of Medicine, University of Tel Aviv, 6 Weizmann St. Tel-Aviv, 6423906, Israel
3 shared publications
Latest Publications
- 1 September 2026
- Published by Wolters Kluwer Health in Neurology Neuroimmunology & Neuroinflammation
- Vol. 13 (5) , e200633
Bispecific Antibodies Are Associated With Progressive Multifocal Leukoencephalopathy
Bispecific antibodies (BisAbs) have transformed the management of relapsed and refractory multiple myeloma (MM), achieving high response rates in heavily pretreated patients. However, these therapies induce profound immune perturbation, including plasma cell aplasia, hypogammaglobulinemia, and T-cell exhaustion, predisposing patients to serious infections. Progressive multifocal leukoencephalopathy (PML) has rarely been reported in this setting. We report on 5 patients with MM who developed PML following BisAbs therapy. Clinical presentation, prior treatments, imaging, CSF studies, pathology, and outcomes were reviewed. In addition, T-cell immunophenotyping and antiviral T-cell responses were evaluated. Five patients (median age 63 years; range 60-77; 3 male) developed PML after treatment with elranatamab (1) or teclistamab (4), with (3) or without (1) talquetamab (1). All patients were under BCMA-directed BisAbs treatment at the time of PML diagnosis. Patients had received a median of 5 prior treatment lines (range 2-7) and 4 had undergone autologous stem cell transplantation. All demonstrated significant immune compromise. Median time from BisAbs initiation to PML diagnosis was 12 months (range 6-24; mean 15.4 months). One patient developed PML after only 2 prior therapies. Three of 5 patients had positive PCR for JC virus (JCV) in the CSF, while the other 2 were positive for JCV on brain biopsy. Clinical manifestations included dysarthria, ataxia, cognitive decline, and focal weakness. Although all patients demonstrated significant immune compromise (lymphopenia and hypogammaglobulinemia), 2 of 4 tested, showed specific anti-JCV/BKV T-cell response. PML represents a rare but serious, life-threatening complication of BisAbs therapy in MM. Although most patients were heavily pretreated, occurrence after limited prior therapies and the presence of specific anti-JCV T cells in 2 patients suggests BisAbs-related immune modulation may contribute independently to the risk. Duration of exposure may also be relevant. Given emerging therapeutic options such as immune check point inhibitors and anti-JCV-specific T-cell therapies, early recognition is critical. PML should be considered in patients receiving BisAbs therapy who develop new neurologic symptoms, and prompt evaluation is warranted.
- 1 September 2026
- Published by Wolters Kluwer Health in Neurology Neuroimmunology & Neuroinflammation
- Vol. 13 (5) , e200633
Bispecific Antibodies Are Associated With Progressive Multifocal Leukoencephalopathy
Bispecific antibodies (BisAbs) have transformed the management of relapsed and refractory multiple myeloma (MM), achieving high response rates in heavily pretreated patients. However, these therapies induce profound immune perturbation, including plasma cell aplasia, hypogammaglobulinemia, and T-cell exhaustion, predisposing patients to serious infections. Progressive multifocal leukoencephalopathy (PML) has rarely been reported in this setting. We report on 5 patients with MM who developed PML following BisAbs therapy. Clinical presentation, prior treatments, imaging, CSF studies, pathology, and outcomes were reviewed. In addition, T-cell immunophenotyping and antiviral T-cell responses were evaluated. Five patients (median age 63 years; range 60-77; 3 male) developed PML after treatment with elranatamab (1) or teclistamab (4), with (3) or without (1) talquetamab (1). All patients were under BCMA-directed BisAbs treatment at the time of PML diagnosis. Patients had received a median of 5 prior treatment lines (range 2-7) and 4 had undergone autologous stem cell transplantation. All demonstrated significant immune compromise. Median time from BisAbs initiation to PML diagnosis was 12 months (range 6-24; mean 15.4 months). One patient developed PML after only 2 prior therapies. Three of 5 patients had positive PCR for JC virus (JCV) in the CSF, while the other 2 were positive for JCV on brain biopsy. Clinical manifestations included dysarthria, ataxia, cognitive decline, and focal weakness. Although all patients demonstrated significant immune compromise (lymphopenia and hypogammaglobulinemia), 2 of 4 tested, showed specific anti-JCV/BKV T-cell response. PML represents a rare but serious, life-threatening complication of BisAbs therapy in MM. Although most patients were heavily pretreated, occurrence after limited prior therapies and the presence of specific anti-JCV T cells in 2 patients suggests BisAbs-related immune modulation may contribute independently to the risk. Duration of exposure may also be relevant. Given emerging therapeutic options such as immune check point inhibitors and anti-JCV-specific T-cell therapies, early recognition is critical. PML should be considered in patients receiving BisAbs therapy who develop new neurologic symptoms, and prompt evaluation is warranted.
- Open Access
- 31 August 2026
- Published by Springer Nature in Scientific Reports
Explainable machine learning analysis of immunology assay patterns among hospitalized patients undergoing immunology testing
- 31 August 2026
- Published by Springer Nature in Scientific Reports
Open AccessExplainable machine learning analysis of immunology assay patterns among hospitalized patients undergoing immunology testing
- Open Access
- 30 July 2026
- Published by Springer Nature in Journal of Clinical Immunology
- Vol. 46 (1)
Biallelic MCM10 Deficiency Presenting with Natural Killer Cell Deficiency, Poikiloderma and EBV-Associated Malignancy
Purpose: Defects in components of the CDC45–MCM2-7–GINS (CMG) helicase complex have been associated with natural killer (NK) cell deficiency in rare inborn errors of immunity. Pathogenic biallelic variants in MCM10 have been reported in a limited number of individuals with severe immunologic and developmental phenotypes. We aimed to further delineate the clinical and immunologic spectrum of MCM10 deficiency. Methods: Singleton exome sequencing, RNA splicing analysis, flow cytometry–based immunophenotyping, telomere length assessment, radiation sensitivity testing, and in silico analysis of publicly available single-cell RNA sequencing datasets were performed. Results: A six-year-old boy presented with poikiloderma, photosensitivity, growth failure, and immune dysregulation. Exome sequencing identified a homozygous canonical splice-site variant in MCM10 (c.930 + 2T > A), resulting in an in-frame deletion of 17 amino acids within the oligonucleotide/oligosaccharide-binding (OB)-fold domain, confirmed at the RNA level.Immunophenotyping showed near-absent NK cells with increased NK-T cells and terminally differentiated CD8 T cells. While karyotype, telomere length, and radiation sensitivity were normal, limited MCM10 expression in replicating NK cells is suspected. During follow-up, the patient developed an aggressive Epstein–Barr virus–positive squamous cell carcinoma of the tongue, an exceedingly rare childhood malignancy. Conclusion: This case expands the phenotypic spectrum of MCM10 -related inborn errors of immunity and supports a critical role for MCM10 in NK-cell development and immune homeostasis. The occurrence of a virus-associated malignancy suggests susceptibility and impaired immune surveillance. Together with previously described defects in CMG-complex components, these findings are consistent with an emerging group of DNA replication–associated immune disorders.
- 30 July 2026
- Published by Springer Nature in Journal of Clinical Immunology
- Vol. 46 (1)
Open AccessBiallelic MCM10 Deficiency Presenting with Natural Killer Cell Deficiency, Poikiloderma and EBV-Associated Malignancy
Purpose: Defects in components of the CDC45–MCM2-7–GINS (CMG) helicase complex have been associated with natural killer (NK) cell deficiency in rare inborn errors of immunity. Pathogenic biallelic variants in MCM10 have been reported in a limited number of individuals with severe immunologic and developmental phenotypes. We aimed to further delineate the clinical and immunologic spectrum of MCM10 deficiency. Methods: Singleton exome sequencing, RNA splicing analysis, flow cytometry–based immunophenotyping, telomere length assessment, radiation sensitivity testing, and in silico analysis of publicly available single-cell RNA sequencing datasets were performed. Results: A six-year-old boy presented with poikiloderma, photosensitivity, growth failure, and immune dysregulation. Exome sequencing identified a homozygous canonical splice-site variant in MCM10 (c.930 + 2T > A), resulting in an in-frame deletion of 17 amino acids within the oligonucleotide/oligosaccharide-binding (OB)-fold domain, confirmed at the RNA level.Immunophenotyping showed near-absent NK cells with increased NK-T cells and terminally differentiated CD8 T cells. While karyotype, telomere length, and radiation sensitivity were normal, limited MCM10 expression in replicating NK cells is suspected. During follow-up, the patient developed an aggressive Epstein–Barr virus–positive squamous cell carcinoma of the tongue, an exceedingly rare childhood malignancy. Conclusion: This case expands the phenotypic spectrum of MCM10 -related inborn errors of immunity and supports a critical role for MCM10 in NK-cell development and immune homeostasis. The occurrence of a virus-associated malignancy suggests susceptibility and impaired immune surveillance. Together with previously described defects in CMG-complex components, these findings are consistent with an emerging group of DNA replication–associated immune disorders.
- Top Cited PapersOpen Access
- 13 March 2026
- Published by Rockefeller University Press in Journal of Human Immunity
- Vol. 2 (3) , e20250189
Autoantibodies neutralizing type I IFNs in 40% of patients with WNV encephalitis in seven new cohorts
Mosquito-borne West Nile virus (WNV) infection is a growing global health problem. About 0.5% of infected individuals develop encephalitis. We previously showed that 40% of patients in six cohorts had WNV encephalitis because of circulating autoantibodies (auto-Abs) neutralizing type I IFNs. In seven new cohorts, we found that the prevalence of auto-Abs was highest (40% [17–44%]) in patients with encephalitis and very low in a small sample of individuals with asymptomatic or mild infection. In the 13 European, Middle Eastern, and American cohorts available, odds ratios (OR) for WNV encephalitis in individuals with these auto-Abs relative to those without them in a large sample of the general population untested for WNV infection range from ∼20 (OR = 17.7; 95% CI: 13.8–22.8, P < 10−16) for auto-Abs neutralizing only 100 pg/ml IFN-α2 and/or IFN-ω to >2,000 (OR = 2,218.4; 95% CI: 125.1–39,337.7, P < 10−16) for auto-Abs neutralizing high concentrations of IFN-α2 and high or low concentrations of IFN-ω. Preexisting auto-Abs neutralizing type I IFNs are therefore causal for WNV encephalitis in about 40% of patients.
- 13 March 2026
- Published by Rockefeller University Press in Journal of Human Immunity
- Vol. 2 (3) , e20250189
Top Cited PapersOpen AccessAutoantibodies neutralizing type I IFNs in 40% of patients with WNV encephalitis in seven new cohorts
Mosquito-borne West Nile virus (WNV) infection is a growing global health problem. About 0.5% of infected individuals develop encephalitis. We previously showed that 40% of patients in six cohorts had WNV encephalitis because of circulating autoantibodies (auto-Abs) neutralizing type I IFNs. In seven new cohorts, we found that the prevalence of auto-Abs was highest (40% [17–44%]) in patients with encephalitis and very low in a small sample of individuals with asymptomatic or mild infection. In the 13 European, Middle Eastern, and American cohorts available, odds ratios (OR) for WNV encephalitis in individuals with these auto-Abs relative to those without them in a large sample of the general population untested for WNV infection range from ∼20 (OR = 17.7; 95% CI: 13.8–22.8, P < 10−16) for auto-Abs neutralizing only 100 pg/ml IFN-α2 and/or IFN-ω to >2,000 (OR = 2,218.4; 95% CI: 125.1–39,337.7, P < 10−16) for auto-Abs neutralizing high concentrations of IFN-α2 and high or low concentrations of IFN-ω. Preexisting auto-Abs neutralizing type I IFNs are therefore causal for WNV encephalitis in about 40% of patients.
- Open Access
Potent Neutralization by Antibodies Targeting the Mpox A28 Protein
SUMMARY: Mpox is the most pathogenic Poxvirus in circulation. While several antigens have been identified as targets for neutralizing antibodies, many proteins remain unexplored. We isolated and characterized four monoclonal antibodies (mAbs) targeting the Mpox A28 (OPG153), a virulence factor present on mature Mpox virions. The antibodies were isolated from convalescent individuals, alongside 14 additional mAbs targeting the A35 and H3 proteins. Anti-A28 mAbs potently neutralized Mpox and Vaccinia virus (VACV) through complement-dependent mechanisms involving C1q and C3 deposition. High resolution crystal structures of Anti-A28 mAbs 10M2146 and 8M2110 in complex with VACV A26 revealed two proximal epitopes within the N-terminal domain. Passive transfer of 8M2110 attenuated disease in infected mice. Moreover, immunization with A28 elicited antigen-specific B cells and robust neutralizing antibody responses and provided complete protection against lethal VACV challenge. These findings support Mpox A28 as a promising target for the induction of neutralizing antibodies and antiviral interventions.
Open AccessPotent Neutralization by Antibodies Targeting the Mpox A28 Protein
SUMMARY: Mpox is the most pathogenic Poxvirus in circulation. While several antigens have been identified as targets for neutralizing antibodies, many proteins remain unexplored. We isolated and characterized four monoclonal antibodies (mAbs) targeting the Mpox A28 (OPG153), a virulence factor present on mature Mpox virions. The antibodies were isolated from convalescent individuals, alongside 14 additional mAbs targeting the A35 and H3 proteins. Anti-A28 mAbs potently neutralized Mpox and Vaccinia virus (VACV) through complement-dependent mechanisms involving C1q and C3 deposition. High resolution crystal structures of Anti-A28 mAbs 10M2146 and 8M2110 in complex with VACV A26 revealed two proximal epitopes within the N-terminal domain. Passive transfer of 8M2110 attenuated disease in infected mice. Moreover, immunization with A28 elicited antigen-specific B cells and robust neutralizing antibody responses and provided complete protection against lethal VACV challenge. These findings support Mpox A28 as a promising target for the induction of neutralizing antibodies and antiviral interventions.
- Open Access
- 20 January 2025
- Published by Elsevier in Autoimmunity Reviews
- Vol. 24 (4) , 103754
Disease-modifying strategies: Targeting protein kinases in multiple sclerosis and other autoimmune disorders
- 20 January 2025
- Published by Elsevier in Autoimmunity Reviews
- Vol. 24 (4) , 103754
Open AccessDisease-modifying strategies: Targeting protein kinases in multiple sclerosis and other autoimmune disorders
- 29 May 2023
- Published by Springer Nature in Journal of Clinical Immunology
- Vol. 43 (7) , 1526-1528
Dupilumab for Post-Hematopoietic Cell Transplantation Dermatitis in Wiskott-Aldrich Syndrome
- 29 May 2023
- Published by Springer Nature in Journal of Clinical Immunology
- Vol. 43 (7) , 1526-1528
Dupilumab for Post-Hematopoietic Cell Transplantation Dermatitis in Wiskott-Aldrich Syndrome
- Open Access
- 15 March 2023
- Published by Elsevier in Autoimmunity Reviews
- Vol. 22 (5) , 103312
Treatment of autoimmunity: The impact of disease-modifying therapies in multiple sclerosis and comorbid autoimmune disorders
- 15 March 2023
- Published by Elsevier in Autoimmunity Reviews
- Vol. 22 (5) , 103312
Open AccessTreatment of autoimmunity: The impact of disease-modifying therapies in multiple sclerosis and comorbid autoimmune disorders